Onderneming Lonza Group AG Börse Stuttgart
Aandelen
LO3A
US54338V1017
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
49,6 EUR | +0,81% | -0,81% | +33,70% |
20/06 | LONZA GROUP AG : Berenberg Bank herhaalt koopadvies | ZM |
14/05 | Zwitserse beursindex loopt op in aanloop naar inflatierapport | MT |
Vakgebied
- biofarmaceutica (55,4%): exclusieve syntheses, microbiologische fermentatieproducten, celculturen van zoogdieren, enz;
- capsules en doseeroplossingen voor biofarmaceutica, geneesmiddelen en voedingsproducten (17,3%). Daarnaast biedt de groep voedingsingrediënten;
- kleine molecule geneesmiddelsubstanties (13,4%);
- technologieën en platforms voor productieprocessen en productie van cel- en gentherapieën (10,4%);
- overige (3,5%).
De netto-omzet is geografisch als volgt verdeeld: Zwitserland (17,4%), Europa (31,7%), de Verenigde Staten (31,8%), Noord- en Zuid-Amerika (3,2%), Japan (8,1%), Azië (7,5%) en overige (0,3%).
Verkoop per activiteit
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Biologics
55,4
%
| 3 274 | 52,6 % | 3 719 | 55,4 % | +13,59% |
Capsules & Health Ingredients
17,3
%
| 1 266 | 20,3 % | 1 161 | 17,3 % | -8,29% |
Small Molecules
13,4
%
| 819 | 13,2 % | 901 | 13,4 % | +10,01% |
Cell & Gene
10,4
%
| 693 | 11,1 % | 696 | 10,4 % | +0,43% |
Corporate/Eliminations
3,6
%
| 171 | 2,7 % | 240 | 3,6 % | +40,35% |
Verkoop per regio
CHF in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
31,8
%
| 2 415 | 38,8 % | 2 136 | 31,8 % | -11,55% |
Switzerland
17,4
%
| 996 | 16,0 % | 1 168 | 17,4 % | +17,27% |
Japan
8,1
%
| 227 | 3,6 % | 544 | 8,1 % | +139,65% |
Ireland
5,5
%
| 343 | 5,5 % | 368 | 5,5 % | +7,29% |
Belgium
5,1
%
| 302 | 4,9 % | 341 | 5,1 % | +12,91% |
Denmark
4,8
%
| 158 | 2,5 % | 322 | 4,8 % | +103,80% |
Germany
4,5
%
| 224 | 3,6 % | 302 | 4,5 % | +34,82% |
Rest of Europe
2,9
%
| 207 | 3,3 % | 195 | 2,9 % | -5,80% |
China
2,6
%
| 161 | 2,6 % | 172 | 2,6 % | +6,83% |
United Kingdom
2,5
%
| 139 | 2,2 % | 171 | 2,5 % | +23,02% |
Singapore
2,0
%
| 113 | 1,8 % | 137 | 2,0 % | +21,24% |
Sweden
1,8
%
| 143 | 2,3 % | 123 | 1,8 % | -13,99% |
France
1,7
%
| 116 | 1,9 % | 111 | 1,7 % | -4,31% |
South Korea
1,4
%
| 141 | 2,3 % | 97 | 1,4 % | -31,21% |
Canada
1,3
%
| 63 | 1,0 % | 90 | 1,3 % | +42,86% |
Netherlands
1,3
%
| 132 | 2,1 % | 88 | 1,3 % | -33,33% |
Brazil
1,1
%
| 49 | 0,8 % | 71 | 1,1 % | +44,90% |
Italy
0,8
%
| 41 | 0,7 % | 52 | 0,8 % | +26,83% |
India
0,6
%
| 42 | 0,7 % | 42 | 0,6 % | 0,00% |
Spain
0,6
%
| 41 | 0,7 % | 40 | 0,6 % | -2,44% |
Mexico
0,5
%
| 34 | 0,5 % | 33 | 0,5 % | -2,94% |
Rest of Asia
0,4
%
| 36 | 0,6 % | 29 | 0,4 % | -19,44% |
Rest of Latin America
0,4
%
| 38 | 0,6 % | 26 | 0,4 % | -31,58% |
Australia & New Zealand
0,2
%
| 21 | 0,3 % | 16 | 0,2 % | -23,81% |
Thailand
0,2
%
| 15 | 0,2 % | 15 | 0,2 % | 0,00% |
Indonesia
0,2
%
| 16 | 0,3 % | 14 | 0,2 % | -12,50% |
Czech Republic
0,2
%
| 7 | 0,1 % | 11 | 0,2 % | +57,14% |
Other Countries
0,0
%
| 2 | 0,0 % | 2 | 0,0 % | 0,00% |
Rest of North and Central America
0,0
%
| 1 | 0,0 % | 1 | 0,0 % | 0,00% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25-04-17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01-12-21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01-08-22 |
Lyle Wheeler
IRC | Investor Relations Contact | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16-04-14 |
Director/Board Member | 66 | 16-04-14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05-05-22 |
Albert Baehny
CEO | Chief Executive Officer | 72 | 25-04-17 |
Christoph Mäder
BRD | Director/Board Member | 64 | 26-04-16 |
Roger Nitsch
BRD | Director/Board Member | 63 | 01-05-22 |
Director/Board Member | 64 | 04-05-18 | |
Director/Board Member | 52 | 04-05-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 74 468 752 | 72 076 913 ( 96,79 %) | 2 352 163 ( 3,159 %) | 96,79 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
LONZA GROUP AG 3.16% | 2 352 163 | 3.16% | 1 268 183 853 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Arch Protection Chemicals Pvt Ltd.
Arch Protection Chemicals Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Lonza Group AG, Arch Protection Chemicals Pvt Ltd. is an Indian company that provides business services. The company is based in Mumbai, India. |
Miscellaneous Commercial Services
|
Capsugel Germany GmbH
| |
Lonza Swiss Finanz AG
Lonza Swiss Finanz AG Finance/Rental/LeasingFinance Lonza Swiss Finanz AG engages in the provision of financing services within the companies of Lonza Group AG. It also invests in domestic and foreign industrial and commercial firms. The company was founded on December 23, 1974 and is headquartered in Basel, Switzerland. |
Finance/Rental/Leasing
|
Arxada AG
Arxada AG Chemicals: Major DiversifiedProcess Industries Arxada AG is a Swiss specialty chemicals company that offers consumer microbial control, industrial microbial control, and specialty product solutions. The company is based in Basel, CH, and has subsidiaries in the Netherlands, United States, and Thailand. The company provides a wide range of differentiated products for various end markets, including hygiene, home and personal care, wood protection, crop protection, and food, beverage, and water. Arxada has leading regulatory capabilities, IP expertise, and an established track record in the industry. C. Marc Doyle has been the CEO of the company since 2021. |
Chemicals: Major Diversified
|
Capsugel FinanceCo SARL
| |
Xcelience Clinical Services Ltd.
Xcelience Clinical Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of MW Encap (Holdings) Ltd., Xcelience Clinical Services Ltd. provides packaging services. The company is based in London, UK. |
Miscellaneous Commercial Services
|
Capsugel Plöermel SASU
Capsugel Plöermel SASU BiotechnologyHealth Technology Capsugel Plöermel SASU designs and manufactures biopharmaceuticals. The company is headquartered in Ploermel, France. |
Biotechnology
|
Capsugel Belgium SA
Capsugel Belgium SA Pharmaceuticals: MajorHealth Technology Capsugel Belgium NV provides dosage forms and solutions. The firm also sells equipment for filling empty and liquid capsules and equipment for sealing liquid capsules. The company was founded on October 1, 1961 and is headquartered in Bornem, Belgium. |
Pharmaceuticals: Major
|
Capsugel Italy SRL
Capsugel Italy SRL Miscellaneous Commercial ServicesCommercial Services Part of Chester Investor Holdings SRL, Capsugel Italy SRL provides management consulting services. The company is based in Milan, Italy. |
Miscellaneous Commercial Services
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,13% | 52,73 mld. | |
-8,73% | 38,52 mld. | |
+28,09% | 30,38 mld. | |
-12,26% | 26,39 mld. | |
+10,57% | 26,08 mld. | |
+45,05% | 14,15 mld. | |
+32,23% | 12,6 mld. | |
-6,56% | 11,51 mld. | |
-12,56% | 10,63 mld. |
- Beurs
- Aandelen
- Koers LONN
- Koers LO3A
- Onderneming Lonza Group AG